Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

EPIGENOMICS Aktie

>EPIGENOMICS Performance
1 Woche: -1,1%
1 Monat: -7,0%
3 Monate: -13,0%
6 Monate: -1,4%
1 Jahr: -1,1%
laufendes Jahr: -3,3%
>EPIGENOMICS Aktie
Name:  EPIGENOMICS AG NA O.N.
Land:  Deutschland
Sektor:  Gesundheit
ISIN/ Wkn:  DE000A37FT41 / A37FT4
Symbol/ Ticker:  ECX (Frankfurt)
Kürzel:  FRA:ECX, ETR:ECX, ECX:GR
Index:  -
Webseite:  https://www.epigenomics.c..
Profil:  Epigenomics AG is a molecular diagnostics company focused on transforming cancer testing through advanced blood-based technologies. Headquartered in Berlin, Germany, the company specializes in developing and globally commercializing innovative biomar..
>Volltext..
Marktkapitalisierung:  0.77 Mio. EUR
Unternehmenswert:  11.82 Mio. EUR
Umsatz:  0.02 Mio. EUR
EBITDA:  -0.34 Mio. EUR
Nettogewinn:  -0.32 Mio. EUR
Gewinn je Aktie:  -0.36 EUR
Schulden:  11.6 Mio. EUR
Liquide Mittel:  0.42 Mio. EUR
Operativer Cashflow:  -
Bargeldquote:  105.7
Umsatzwachstum:  -
Gewinnwachstum:  90.63%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  EPIGENOMICS
Letzte Datenerhebung:  06.06.26
>EPIGENOMICS Kennzahlen
Aktien/ Unternehmen:
Aktien: 0.88 Mio. St.
Frei handelbar: 85%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: -
Umsatz/Mitarb.: -
Analysten:
Analystenrating: No rating
Kursziel: -
Bewertung:
KGV: -
KGV lG: -
KUV: 31.79
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -1308.33%
Operative Marge: -1400%
Managementeffizenz:
Gesamtkaprendite: -43.89%
Eigenkaprendite: -
>EPIGENOMICS Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung
 
19.05.26 - 16:03
EpiCypher and New England Biolabs Expand Strategic Partnership to Advance Epigenomics Research (PR Newswire)
 
DURHAM, N.C. and IPSWICH, Mass., May 19, 2026 /PRNewswire/ -- EpiCypher® and New England Biolabs® (NEB®) today announced an expanded strategic partnership to co-develop next-generation tools for epigenomics research. Building on a successful track record of collaboration, the partnership......
15.04.26 - 14:06
ClearNote Health to Showcase Industry-Leading Early Detection Performance of the Avantect® Pancreatic Cancer Test at AACR Annual Meeting 2026 (Business Wire)
 
SAN DIEGO--(BUSINESS WIRE)--#5hmC--ClearNote Health, a company dedicated to improving early detection for some of the deadliest cancers, today announced a lineup of presentations at the upcoming annual meeting of the American Association for Cancer Research (AACR) in San Diego, taking place April 17-22. Attendees at the AACR Annual Meeting 2026 can meet with ClearNote Health's scientific leaders, including newly appointed Chief Medical Officer, Jeffrey Venstrom, MD. At booth 3448, the company will showcase its Virtuoso™ epigenomics platform for drug development, as well as its enhanced Avantect® Pancreatic Cancer Test, which now delivers industry-leading detection sensitivity of 82.6% and specificity of 97.5% for patients at elevated risk of this disease. “ClearNote Health is eager to share with the cancer research community the significant advances we've made with our 5hmC technology for early cancer detection and drug development,” said Dr. Venstrom. “Our Virtuoso platform empowers researcher...
25.02.26 - 15:18
Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics (PR Newswire)
 
At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing,......
23.02.26 - 18:03
New Gentle Methyl Conversion Kit Delivers High-Accuracy Profiling from as Little as 100 pg of DNA (PR Newswire)
 
New commercial kit brings Nature Communications-validated methylation analysis chemistry to researchers working with low-input and cfDNA samples CAMBRIDGE, Mass., Feb. 23, 2026 /PRNewswire/ -- Ellis Bio, a developer of next-generation epigenomics technologies, today announced the official......
05.09.25 - 19:45
PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq (Zacks)
 
PacBio collaborates with EpiCypher to integrate Fiber-Seq and HiFi sequencing, advancing single-molecule epigenomics with new chromatin mapping tools....
03.09.25 - 15:09
PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow (GlobeNewswire EN)
 
New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer...
10.07.25 - 17:06
Vorläufiges Halbjahresergebnis zum 30. Juni 2025 (Pressetext)
 
Um den gesamten Artikel unter adhoc.pressetext.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Man möchte wirklich sagen: Die Menschen sind die Teufel auf Erden und die Tiere die geplagten Seelen. - Arthur Schopenhauer
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!